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at clinicians, and not regulators. 
Furthermore, we specifically ack­
nowledged the limitations of our 
proposed model and noted in 
particular that difficult­to­treat 
depression is insufficient to define 
clinical populations for regulatory 
trial purposes. Importantly, we 
intentionally did not indicate where 
in any particular treatment algorithm 
specific treatments should be used. 
Instead, we highlighted an earlier 
paper that argued for a threshold 
well above conventional definitions 
of treatment­resistant depression 
and including multiple therapeutic 
modalities, which could help clinicians 
decide when it might be appropriate 
to utilise potentially more risky and 
expensive treatments.5
Finally, it is important to note 
that the proposed difficult­to­treat 
depression model of care is not 
appropriate for all patients with 
depression, and not even for all those 
who would normally be classified 
as having treatment­resistant 
depression. However, the model is 
a useful concept for both patients 
and clinicians when management is 
mutually perceived as difficult, because 
it serves the aim of averting the 
development of therapeutic nihilism.
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We are heartened that our consen­
sus statement1 on difficult­to­
treat depres sion has provoked 
robust debate. As pointed out by 
Lisa Cosgrove and colleagues,2 our 
proposed definition and model of 
care for difficult­to­treat depression 
is not derived from a systematic 
review or a Delphi technique. The 
term difficult­to­treat depression had 
previously been proposed to address 
semantic and conceptual issues with 
the so­called treatment­resistant 
depression model, for patients where 
achieving sustained remission proves 
elusive.3 We aimed to extend the 
discussion regarding this proposal, 
focusing on practical clinical advice. 
As the concept of difficult­to­treat 
depression is new, there is no literature 
to systematically review. The literature 
around the management of so­called 
treatment­resistant depression has 
been reviewed on many occasions, 
but this literature was only of partial 
relevance to our aims. Not only is there 
no universally accepted definition 
of treatment­resistant depression, 
but those that are used rarely if ever 
take into account psychotherapeutic 
or neurostimulatory treatments, 
or how to account for differential 
efficacy among treatments.4,5 At the 
core of the proposed difficult­to­treat 
depression model is the importance 
of taking a holistic approach and 
considering all treatment options 
available. A systematic review of all 
treatments for depression was not 
practical. As a result, our consensus 
was based on the culmination of 
extensive discussion and deliberation 
among 15 international experts in 
the management of depression from 
across three continents, and the 
national guidelines for the treatment 
of depression from the countries 
represented. Rather than through 
a Delphi technique, we arrived at a 
consensus through many iterative 
reviews of the manuscript until all 
15 contributors were comfortable with 
all the statements being discussed. 
However, we wish to clarify two key 
points that we feel Cosgrove and 
colleagues might have misunderstood.
First, they argue that a better way 
to address deficiencies of the current 
treatment­resistant depression model 
is to strive for a better understanding 
of why treatment success remains 
low for some patients. We fully 
agree with this statement, and this is 
precisely the central tenet behind the 
difficult­to­treat depression model. 
We suggest that when depression is 
proving difficult to treat, the next step 
is for the clinician, collaboratively with 
the patient, to do a comprehensive 
biopsychosocial assessment of the 
factors relevant to this, addressing any 
that are tractable using all appropriate 
therapeutic modalities. Thus, the 
difficult­to­treat depression model 
does precisely what Cosgrove and 
colleagues argue that it should.
Second, Cosgrove and colleagues’ 
main concern regarding the difficult­
to­treat depression model is that 
they view it as a diagnostic label that 
is broader and even more susceptible 
to subjective interpretations than 
treatment­resistant depression. They 
suggest that study sponsors could 
easily take advantage of such loose 
criteria when designing pivotal trials 
for new drug applications. We concur 
that broadening diagnostic criteria 
can have negative consequences 
including overmedicalisation and 
might, as Cosgrove and colleagues 
have suggested, erode the threshold 
above which riskier and more 
expensive treatments are offered 
to patients. However, once again it 
seems that what we mean by the term 
difficult­to­treat depression has been 
misunderstood. We are not professing 
that the term is a diagnosis per se, but 
rather a framework or model of care. 
We stipulated in our consensus paper 
that the model was aimed primarily 
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News reporting on suicidal behaviour 
can have a considerable influence on 
suicide and self­harm in the general 
population.1 This issue is particularly 
relevant during the COVID­19 
pandemic. With a rising number of 
deaths from COVID­19 infection and 
negative effects of the pandemic on 
key factors that are associated with 
suicide, including social isolation, 
unemployment, and financial 
problems, there is understandable 
concern that suicide rates might 
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